• Japan – Asia Life Science Showcase @RESI JPM 2027

    Please confirm your attendance for the Japan – Asia Life Science Showcase at RESI JPM 2027. Review the event details below and submit your RSVP.
  •  

    🔬 Japan – Asia Life Science Showcase
    📅 Date & Time: Monday, January 11, 1:00 - 3:00pm PST
    📍 Location: Salon 15 Room (in Yerba Buena Ballroom), Marriott Marquis San Francisco, 780 Mission St, San Francisco, CA 94103

    As Title Sponsor of RESI JPM 2027, Kobe Biomedical Innovation Cluster (KBIC) is proud to host a special pitching session at RESI JPM 2027 featuring a curated group of emerging Japanese life science innovators.



    This 2-hour session will feature 8 innovative companies from Japan - Asia, with each company delivering a 6 minute pitch, followed by 7 minute Q&A. 

    All registered RESI JPM 2027 attendees are welcome to join.

  • Are you already registered for RESI JPM 2027?*
  • This event is only open to registered attendees of RESI JPM 2027.
    You are unable to submit your RSVP at this time.

  • Will you attend the Japan – Asia Life Science Showcase ?*
    • ⬇️ Learn More About the 8 Presenting Companies 
    • Toregem BioPharma Co., Ltd.
      Toregem BioPharma is developing a groundbreaking approach to tooth regeneration through its lead antibody candidate, TRG035, targeting USAG-1 to stimulate natural tooth development. Following Phase I clinical development, the company is advancing its program toward treating congenital tooth agenesis, with the potential to transform dental and regenerative medicine.

      Crafton Biotechnology Co., Ltd.
      Crafton Biotechnology is leveraging its proprietary PureCap® mRNA platform to develop next-generation therapeutics that enable sustained antibody production within the body. By potentially reducing treatment frequency and improving patient convenience, the company aims to address unmet medical needs in autoimmune and other chronic diseases.

      A-SEEDS Co., Ltd.
      A-SEEDS is advancing innovative CAR-T cell therapies targeting acute myeloid leukemia and solid tumors. Utilizing its proprietary non-viral piggyBac transposon platform, the company is developing durable, tumor-selective cell therapies designed to overcome key limitations of conventional CAR-T treatments.

      Arrowsmith Inc.
      Arrowsmith is harnessing synthetic biology to develop engineered bacteriophage therapies targeting antimicrobial-resistant infections. Its precision-based approach selectively eliminates harmful bacteria, including Pseudomonas aeruginosa, offering a potential alternative to conventional antibiotics in addressing the growing global antimicrobial resistance crisis.

      LIFESCAPES Inc.
      LIFESCAPES is developing non-invasive brain-computer interface (BCI) technology designed to restore hand movement in patients with severe paralysis resulting from stroke or spinal cord injury. By integrating brain signal monitoring, advanced software, and robotic assistance, its technology aims to improve rehabilitation outcomes and patients' quality of life.

      Periotherapia Co., Ltd.
      Periotherapia is developing innovative antibody therapies targeting pathological periostin, a key component of the tumor microenvironment associated with treatment resistance. By disrupting protective barriers surrounding tumors, its approach aims to enhance drug penetration and improve the effectiveness of existing cancer therapies.

      CynosBio, Inc.
      CynosBio specializes in autologous cell therapies addressing unmet needs in ophthalmology and orthopedics. Its portfolio includes Sakracy, an approved regenerative therapy for severe ocular surface disorders in Japan, alongside a Phase III knee cartilage regeneration program, positioning the company for potential international clinical development and commercialization.

      Mustbio Co., Ltd.
      Mustbio is advancing next-generation cancer immunotherapies through its proprietary multi-specific antibody platform. Its tri-specific fusion protein targets PD-1, VEGF, and IL-21 pathways to enhance anti-tumor immune responses and potentially overcome resistance to existing immunotherapies, particularly in patients with refractory or relapsed cancers.

       

    • ⬇️ Learn More About Kobe Biomedical Innovation Cluster (KBIC) 
    • Kobe Biomedical Innovation Cluster: Gateway to Japan's Largest Biocluster Innovation Community 

      The Kobe Biomedical Innovation Cluster (KBIC) was established as part of Kobe’s post-earthquake revitalization strategy and has since grown into Japan’s largest biomedical cluster. Founded in 1998, KBIC now brings together more than 370 companies, research institutes, universities, and specialized hospitals, creating a highly collaborative environment for advancing medical devices, regenerative medicine, pharmaceuticals, diagnostics, and digital health technologies. Its mission is to accelerate innovation, support commercialization, and strengthen Japan’s life science ecosystem by connecting industry, academia, and clinical institutions.

      Located on Port Island with convenient access to Kobe Airport and high-speed rail, KBIC offers a dense concentration of resources including advanced research facilities, hospital and clinical infrastructure, wet labs, shared equipment, and rental lab or office space. Through the Foundation for Biomedical Research and Innovation at Kobe (FBRI), the cluster provides extensive support services such as regulatory guidance, startup incubation, business development assistance, and international partnership programs. Together, these assets make KBIC one of Asia’s leading hubs for life science innovation and global collaboration.

      >> For more information, please visit https://www.fbri-kobe.org/kbic/english. 

    • Should be Empty: